Dr Langer speaks with ecancertv at ESMO 2016 about the results from the KEYNOTE-021 trial.

The trial found that the addition of pembrolizumab, a PD-1 antibody, to standard first-line chemotherapy for treatment-naive advanced NSCLC achieved significantly longer progression free survival, a great objective response rate, and a well-tolerated toxicity profile.

Video of the press conference in which Dr Langer announced these results can be watched here.

More details are available in the trial data published in The Lancet, and reported on in ecancer news here.

These results complement those presented by Dr Martin Reck, who discussed results from KEYNOTE-024 which recommend pembrolizumab as a firstline therapy for NSCLC patients with high levels of PDL-1 expression.